---
title: "Sensei Biotherapeutics | 8-K: FY2026 Q1 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286557759.md"
datetime: "2026-05-15T11:36:54.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286557759.md)
  - [en](https://longbridge.com/en/news/286557759.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286557759.md)
---

# Sensei Biotherapeutics | 8-K: FY2026 Q1 Revenue: USD 0

Revenue: As of FY2026 Q1, the actual value is USD 0.

EPS: As of FY2026 Q1, the actual value is USD -131.45, missing the estimate of USD -0.62.

EBIT: As of FY2026 Q1, the actual value is USD -170.63 M.

#### Cash Position

Cash, cash equivalents and marketable securities for Sensei Biotherapeutics, Inc. were $202.8 million as of March 31, 2026, a significant increase from $21.2 million as of December 31, 2025.

#### Research and Development (R&D) Expenses

R&D expenses for the quarter ended March 31, 2026, were $18.0 million, compared with $3.7 million for the same quarter in 2025. The increase was primarily due to the inclusion of Faeth R&D operations and one-time costs associated with the Faeth acquisition, partially offset by reduced SNS-101 clinical trial costs.

#### General and Administrative (G&A) Expenses

G&A expenses totaled $19.7 million for the quarter ended March 31, 2026, up from $3.5 million for the quarter ended March 31, 2025. This increase was mainly attributable to one-time costs related to the Faeth acquisition.

#### Acquired In-Process Research and Development (Acquired IPR&D) Expenses

Acquired IPR&D expenses were $133.0 million for the quarter ended March 31, 2026, representing the fair value of IPR&D assets obtained from the asset acquisition where the acquired IPR&D had no alternative future use.

#### Net Loss

Sensei Biotherapeutics, Inc. reported a net loss of - $170.2 million for the quarter ended March 31, 2026, compared with a net loss of - $6.9 million for the quarter ended March 31, 2025.

#### Net Loss Per Share

Net loss per basic and diluted share was - $131.45 for the quarter ended March 31, 2026, versus - $5.45 for the same period in 2025.

#### Weighted-Average Common Shares Outstanding

Weighted-average common shares outstanding, basic and diluted, were 1,295,052 for the quarter ended March 31, 2026, compared with 1,259,531 for the quarter ended March 31, 2025.

#### Balance Sheet Data

As of March 31, 2026, total assets were $205.381 million, and total liabilities were $14.191 million. Total stockholders’ deficit was - $137.286 million as of March 31, 2026, compared to a total stockholders’ equity of $18.592 million as of December 31, 2025.

#### Operational Highlights

Sensei Biotherapeutics, Inc. dosed the first patient in the Phase 1b/2 trial evaluating PIKTOR for the treatment of HR+/HER2- advanced breast cancer in April 2026.

#### Outlook / Guidance

Interim data from the PIKTOR Phase 1b/2 trial in HR+/HER2- advanced breast cancer is expected in 2027. Topline Phase 2 data for PIKTOR in advanced endometrial cancer is on track to report in the second half of 2026. The $200 million private placement in February 2026 is expected to fund Sensei Biotherapeutics, Inc. through key clinical milestones.

### Related Stocks

- [SNSE.US](https://longbridge.com/en/quote/SNSE.US.md)

## Related News & Research

- [Sensei Biotherapeutics reports $170.2M Q1 net loss, $202.8M cash position](https://longbridge.com/en/news/286559285.md)
- [The Home Depot Announces First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guidance | HD Stock News](https://longbridge.com/en/news/286890512.md)
- [ZKH Group Limited Announces First Quarter 2026 Unaudited Financial Results | ZKH Stock News](https://longbridge.com/en/news/287196025.md)
- [GDEV announces results for the first quarter of 2026 | GDEV Stock News](https://longbridge.com/en/news/286909689.md)
- [Advance Auto Parts Reports First Quarter 2026 Results; Reaffirms Full Year 2026 Guidance | AAP Stock News](https://longbridge.com/en/news/287202242.md)